interval, 1.8-17.8; P ¼ .002) were independent predictors for the development of neurologic impairment. An interaction term between cLEIT and CIA lumen of 8 mm or less was significant statistically (P ¼ .042), indicating that the presence of small CIA lumen modifies the effect of cLEIT. As shown in the Fig, in patients with CIA lumen of 8 mm or less, the risk of neurologic impairment increases rapidly after 2.5 hours of LE ischemia and becomes nearly certain after 4 hours of ischemia time. In contrast, patients with a larger CIA can tolerate a longer duration of ischemia and demonstrate a less steep rise in the risk for LE neurologic impairment.
Background: The purpose of this study was to describe changes in renal volumes and renal function after fenestrated-branched endovascular aneurysm repair (F-BEVAR) for complex aortic aneurysms.
Methods: Between July 2012 and April 2017, patients enrolled in a physician-sponsored investigational device exemption clinical trial for the endovascular treatment of complex aortic aneurysms had data analyzed retrospectively. The prospectively maintained database included preoperative demographics, comorbidities, preoperative computed tomography angiography results, duplex ultrasound findings, perioperative data, and follow-up outcomes. Descriptive statistics were calculated using mean and standard deviations. Mean estimated glomerular filtration rate (eGFR) and renal volumes were calculated for baseline and each time point (6, 12, and 18 months after the procedure). A linear model was used with generalized estimating equations to determine renal volume predictive modeling of eGFR and adjusted for patient characteristics and comorbidities. The analysis was also adjusted for the patient's preoperative renal status and the presence of accessory renal arteries.
Results: During the study period, 139 patients were included for analysis and followed up for 18 months or until death. The mean age was 71 6 8 years; 70% were male. The most common risk factors were smoking history (94%) and hypertension (92% ; Table) . Chronic kidney disease (eGFR <60 mL/min) was present in 40% (56/139). Thirty-one patients (22%) had at least one accessory renal artery, 87% (27/31) of which were embolized or covered. On average, eGFR changed over time with a mean decrease of 4.6 (615.2) mL/min, 3.8 (615.4) mL/min, and 5.0 (615.9) mL/min compared with baseline at the 6-, 12-, and 18-month follow-up time intervals, respectively. Similarly, renal volumes decreased from baseline: 8% (617), 10% (617), and 11% (622) at 6, 12, and 18 months, respectively. An increase in the patient's age of 5 years was estimated to be associated with a decrease of 2.9 mL/min in eGFR, which is similar to the natural history of renal deterioration with age. There was an estimated decrease of 1 cm 3 in renal volume for each decrease of 0.05 mL/min in eGFR (P ¼ .047). The average change in renal volumes among patients with and without previous chronic kidney disease was not statistically different. Interestingly, 16.1% (9/56) of patients with previous chronic kidney disease had improvement in the eGFR to >60 mL/min, all of whom were stage 3. The mean follow-up for the cohort was 14.3 months. Kaplan-Meier survival at 1 year and 2 years was 84.7% and 78.8%.
Conclusions: Renal volume and eGFR decreased in patients undergoing repair at rates similar to natural history progression. The eGFR was found to moderately correlate with renal volume. Most accessory renal arteries can be excluded without significant impact on renal function. The majority of the decline in renal function occurred within the first 6 months postoperatively, after which stabilization was observed, suggesting little impact of F-BEVAR on renal function during the initial 18 months after treatment. Background: Thoracic endovascular aortic repair (TEVAR) has become the mainstay for treatment of acute, complicated type B dissection (TBAD). Similarly, TEVAR has been increasingly used to manage chronic TBAD with aneurysmal degeneration. Dynamic aortic morphology with TBAD may have significant consequences for TEVAR durability. However, few descriptions contrast the differences in secondary aortic intervention (SAI) after TEVAR for acute and chronic TBAD. The purpose of this analysis was to examine the incidence, timing, and types of SAI after TEVAR for acute and chronic TBAD and to describe SAI impact on survival.
Methods 
